Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

CUL4A abrogation augments DNA damage response and protection against skin carcinogenesis.

Molecular cell | 2009

It is intuitively obvious that the ability of a cell to repair DNA damage is saturable, either by limitation of enzymatic activities, the time allotted to achieve their function, or both. However, very little is known regarding the mechanisms that establish such a threshold. Here we demonstrate that the CUL4A ubiquitin ligase restricts the cellular repair capacity by orchestrating the concerted actions of nucleotide excision repair (NER) and the DNA damage-responsive G1/S checkpoint through selective degradation of the DDB2 and XPC DNA damage sensors and the p21/CIP1/WAF1 checkpoint effector. We generated Cul4a conditional knockout mice and observed that skin-specific Cul4a ablation dramatically increased resistance to UV-induced skin carcinogenesis. Our findings reveal that wild-type cells do not operate at their full DNA repair potential, underscore the critical role of CUL4A in establishing the cellular DNA repair threshold, and highlight the potential augmentation of cellular repair proficiency by pharmacological CUL4A inhibition.

Pubmed ID: 19481525 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: R01 CA098210-04
  • Agency: NIEHS NIH HHS, United States
    Id: R01 ES014482-04
  • Agency: NCI NIH HHS, United States
    Id: R01 CA098210-06A1
  • Agency: NCI NIH HHS, United States
    Id: R56 CA098210-06
  • Agency: NCI NIH HHS, United States
    Id: R01 CA098210-05
  • Agency: NCI NIH HHS, United States
    Id: R01 CA118085
  • Agency: NCI NIH HHS, United States
    Id: R01 CA098210-03
  • Agency: NCI NIH HHS, United States
    Id: CA098210
  • Agency: NCI NIH HHS, United States
    Id: R01 CA118085-04
  • Agency: NIEHS NIH HHS, United States
    Id: ES014482
  • Agency: NCI NIH HHS, United States
    Id: R01 CA118085-03
  • Agency: NIEHS NIH HHS, United States
    Id: R01 ES014482
  • Agency: NCI NIH HHS, United States
    Id: R01 CA118085-02
  • Agency: NCI NIH HHS, United States
    Id: R01 CA118085-01
  • Agency: NCI NIH HHS, United States
    Id: R01 CA098210
  • Agency: NCI NIH HHS, United States
    Id: R01 CA098210-01A1
  • Agency: NCI NIH HHS, United States
    Id: R01 CA098210-02
  • Agency: NCI NIH HHS, United States
    Id: CA118085
  • Agency: NCI NIH HHS, United States
    Id: R56 CA098210

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Cell Signaling Technology (tool)

RRID:SCR_004431

Privately held company that develops and produces antibodies, ELISA kits, ChIP kits, proteomic kits, and other related reagents used to study cell signaling pathways that impact human health.

View all literature mentions